Clinical Trial AgreementClinical Trial Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This Clinical Trial Agreement (“Agreement”) is made on 1/26/2018 (the “Effective Date”) by and between St. Joseph Heritage Healthcare (“Institution”), a California nonprofit public benefit corporation with an address at 200 W. Center Street Promenade, Suite 800, Anaheim, California 92805; Jarrod Holmes, M.D. (“Principal Investigator”), a contractor of Institution with an office located at 3555 Round Barn Circle, Santa Rosa, CA 95403, and Cancer Insight, LLC (“CRO”), a limited liability company having its principal place of business at 110 E. Houston Street, San Antonio, TX 78205. CRO, Institution and Principal Investigator are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
SHARE EXCHANGE AGREEMENTShare Exchange Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
NOW THEREFORE THIS AGREEMENT WITNESSETH THAT in consideration of the mutual promises and covenants contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby covenant and agree as follows:
SERVICE AGREEMENTService Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • Colorado
This Service Agreement (“Agreement”) is entered into by and between The Board of Governors of The Colorado State University System, acting by and through Colorado State University, an institution of higher education of the State of Colorado, located at Fort Collins, Colorado, 80523-2002 (“University”), and the Sponsor, BriaCell Therapeutics Incorporated (“Sponsor”), collectively referred to as “Parties” and is effective 2017 September 1.
Amendment No. 2 to UNIVERSITY Agreement No. S15-00193VAgreement for Services • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
Parties to this Amendment: The Regents of the University of California, acting for and on behalf of University of California, Davis Health (“UNIVERSITY”).
AGREEMENT FOR SERVICESAgreement for Services • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • California
This Agreement for Services (“Agreement”) is made by and between The Regents of the University of California, a California constitutional corporation, acting for and on behalf of its University of California, Davis Health System (“UNIVERSITY”), and Briacell Therapeutics Corp., a private California corporation, (“COMPANY”). UNIVERSITY and COMPANY are referred to individually as a “Party” and collectively as the “Parties”.
HLA Typing Service AgreementHla Typing Service Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • New York
Consulting AgreementConsulting Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • California
This CONSULTING AGREEMENT (the “Agreement”) is entered into as of the October 16, 2019, and effective as of November 1, 2016 (The “Effective Date”).
FIRST AMENDMENT TO THE CLINICAL TRIAL AGREEMENTClinical Trial Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This First Amendment to the Clinical Trial Agreement (“First Amendment”) is made on 2019 May 7, 2019 (“Effective Date”) by and between St. Joseph Heritage Healthcare (“Institution”) and Cancer Insight, LLC (“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
FIRST SUPPLEMENT TO THE CLINICAL STUDY AGREEMENTClinical Study Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This First Supplement to the Clinical Study Agreement (the “First Supplement”) is made on the last day of signature (the “Effective Date”) and is made by and between Cancer Insight, LLC (“Cancer Insight”) and BriaCell Therapeutics Corporation (“BriaCell”) (each a “Party” and collectively the “Parties”).
Amendment No. 1 to UNIVERSITY Agreement No. S15-00192NDReciprocal Nondisclosure Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
Parties to this Amendment: The Regents of the University of California, acting for and on behalf of its University of California, Davis Health System (“UNIVERSITY”).
FIRST AMENDMENT TO THE CLINICAL TRIAL AGREEMENTClinical Trial Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This First Amendment to the Clinical Trial Agreement (“First Amendment”) is made on August 28, 2018 (“Effective Date”) by and between Cancer Center of Kansas (“Institution”) and Cancer Insight, LLC (“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
AGREEMENTConfidentiality Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • Colorado
This Agreement (the “Agreement”), entered into this 16th day of March, 2017 (“the “Effective Date”), by and between Faller & Williams Technology LLC, with a place of business at 1809 Linden Lake Road, Fort Collins, CO 80524 (“FWT”) and Sapientia Pharmaceuticals, Inc., with a place of business at 2015 N. Federal Hwy, #303, Delray Beach, FL 33483 (“Sapientia”), collectively referred to hereinafter as the “Parties” or individually referred to hereinafter as a “Party”.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • British Columbia
BriaCell Therapeutics Corp., a company incorporated under the laws of Delaware and having its office at 820 Heinz Avenue, Berkeley, CA, USA, 94710
Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of July 23, 2018 (“Effective Date”) by and between Thomas Jefferson University, a Pennsylvania non-profit corporation (“Institution”), having an address at 125 S. 9th Street, Second Floor Sheridan, Philadelphia, PA 19107, and Cancer Insight, LLC, a limited liability company having its principal place of business at 110 East Houston Street, Floor Seven, San Antonio, TX 78205 (“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
